epoetin-alfa has been researched along with Hematologic-Diseases* in 11 studies
2 review(s) available for epoetin-alfa and Hematologic-Diseases
Article | Year |
---|---|
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
Hematologic side effects (anemia, neutropenia, and thrombocytopenia) of combination therapy with pegylated (PEG)-interferon alfa and ribavirin are commonly encountered during antiviral therapy for chronic hepatitis C (HCV). An important consequence of these side effects is dose modification of PEG-interferon alfa, ribavirin, or both. Dose modification (including discontinuation) diminishes the efficacy of optimal treatment regimen for HCV and may have a negative impact on sustained virologic response. Additionally, fatigue associated with anemia may impair patients' quality of life. The clinical implications of neutropenia or thrombocytopenia are less clear than for anemia; nevertheless, severe infection and bleeding are uncommon. Dose adjustments effectively treat these hematologic side effects, but the resulting suboptimal dosing and potential impact on virologic response are major concerns. Recent attempts to maximize adherence to the optimal treatment regimen have used hematopoietic growth factors rather than dose adjustment to treat side effects. Research on growth factor support has focused on anemia and neutropenia. Epoetin alfa and darbepoetin alfa are erythropoietic growth factors that effectively increase hemoglobin while maintaining the optimal ribavirin dose and improving patients' quality of life. Preliminary work suggests that filgrastim, granulocyte colony stimulating factors, may be an effective treatment of interferon-induced neutropenia. Although this early work shows tremendous promise for managing hematologic side effects of combination therapy for HCV, and potentially enhancing adherence, further research is needed to clarify the efficacy, safety, and cost-effectiveness of growth factors in the management of patients with chronic HCV. Topics: Anemia, Hypochromic; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Granulocyte Colony-Stimulating Factor; Growth Substances; Hematinics; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Management of the hematologic complications of hepatitis C therapy.
Consensus guidelines are in place for treating chronic hepatitis C virus infection. This article highlights some of the hematologic complications of hepatitis C therapy. Management options are presented. Topics: Anemia; Antiviral Agents; Bone Marrow; Epoetin Alfa; Erythropoietin; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
9 other study(ies) available for epoetin-alfa and Hematologic-Diseases
Article | Year |
---|---|
Hematologic abnormalities in children and young adults receiving tacrolimus-based immunosuppression following cardiothoracic transplantation.
To define the incidence, course, and etiology of hematologic abnormalities in children on tacrolimus-based immunosuppression, we reviewed records of 106 transplant patients (70 heart, 16 heart and lung, 20 double lung), 0-21 yr of age, who were transplanted at the Children's Hospital of Pittsburgh from 1989 to 1997. Fifty-four of the 106 patients (51%) developed 65 abnormal hematologic episodes (32 anemia, nine neutropenia, nine thrombocytopenia, 15 simultaneous anemia and neutropenia with or without thrombocytopenia). Common etiologies included: infections, post-transplant lymphoproliferative disease, and medications. Eleven episodes (seven anemia, one neutropenia, and three simultaneous anemia and neutropenia) had unclear etiologies and process of elimination suggested an association with tacrolimus. Interventions included filgrastim (effective in 15 of 15 patients, with resolution of neutropenia in a median of 5 days) and epoetin alfa (effective in five of 16 patients, including four of four patients with anemia possibly related to tacrolimus). Five patients (two with neutropenia and three with simultaneous neutropenia and anemia) were switched to cyclosporin A (CsA); rapid resolution occurred in four of the five patients, suggesting a possible association of the hematologic abnormalities with tacrolimus. In summary, hematologic abnormalities are common in children on tacrolimus-based immunosuppression. Most of these hematologic abnormalities are caused by common etiologies; however, a sub-population exists where tacrolimus may be the etiologic agent. Anemia and neutropenia respond to treatment with epoetin alfa and filgrastim. After thorough investigation, a trial switch to CsA may be warranted. Topics: Adolescent; Adult; Anemia; Child; Child, Preschool; Epoetin Alfa; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Transplantation; Heart-Lung Transplantation; Hematologic Diseases; Humans; Immunosuppressive Agents; Infant; Lung Transplantation; Male; Neutropenia; Recombinant Proteins; Retrospective Studies; Tacrolimus; Thrombocytopenia | 2001 |
[CURRENT TRENDS IN HEMATOLOGY. 5. REGULATION OF ERYTHROPOIESIS].
Topics: Epoetin Alfa; Erythropoiesis; Erythropoietin; Hematologic Diseases; Hematology; Humans | 1965 |
[BLOOD DISEASES].
Topics: Anemia; Anemia, Hemolytic; Anemia, Hypochromic; Anemia, Pernicious; Blood Coagulation; Blood Proteins; Chloramphenicol; Epidemiology; Epoetin Alfa; Erythropoietin; Haptoglobins; Hematologic Diseases; Hematology; Hemochromatosis; Humans; Iron-Dextran Complex; Leukemia; Polycythemia; Thromboplastin; Vitamin B 12 | 1964 |
[ERTHROPOIETIN].
Topics: Epoetin Alfa; Erythropoiesis; Erythropoietin; Hematologic Diseases; Humans; Kidney Diseases | 1964 |
[On the importance of erythropoietin for clinical hematology].
Topics: Blood Physiological Phenomena; Epoetin Alfa; Erythrocytes; Erythropoietin; Hematologic Diseases; Hematology; Humans | 1962 |
Relation between severity of anemia and erythropoietin titer in human beings.
Topics: Anemia; Anemia, Hypochromic; Epoetin Alfa; Erythrocytes; Erythropoietin; Hematologic Diseases; Humans | 1961 |
Erythropoietin as an etiologic factor in blood dyscrasias.
Topics: Anemia; Epoetin Alfa; Erythrocytes; Erythropoietin; Hematologic Diseases; Hematopoiesis; Humans; Hypoxia | 1961 |
[Erythropoietin. (Research on a substance increasing erythropoies is in blood diseases)].
Topics: Epoetin Alfa; Erythrocytes; Erythropoietin; Hematologic Diseases; Hematopoiesis; Research | 1960 |
[Incidence and importance of erythropoietin in erythroblastosis fetalis].
Topics: Epoetin Alfa; Erythroblastosis, Fetal; Erythropoietin; Fetal Blood; Hematologic Diseases; Incidence | 1957 |